Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Hematology
Prevalence
30.0 / 100K
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)?
There are 1 clinical trial targeting Post-essential Thrombocythemia Myelofibrosis(Post-ET MF) tracked by BioSniper.
What is the prevalence of Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)?
The estimated prevalence of Post-essential Thrombocythemia Myelofibrosis(Post-ET MF) is approximately 30.0 per 100,000 population.
Deep-dive into Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis